Rigosertib sodium - ON01910 sodium | Estybon

Based on 99 reference(s) in Google Scholar 8 10 99

Axon 2950

CAS [592542-60-4]

MF C21H24NNaO8S
MW 473.47

  • Purity: 99%
  • Soluble in water and DMSO
Recently added

Rigosertib sodium

Description

Rigosertib sodium is a non-ATP-competitive inhibitor of PLK1 (IC50 value of 9–10 nM) which induces mitotic arrest of tumor cells characterized by spindle abnormalities leading to their apoptosis. In vitro studies with Rigosertib sodium showed that incubation of human leukemic cells with this compound results in the inhibition of PI3K/AKT pathway, down regulation of cyclin D1, induction of NOXA and BIM and activation of JNK pathway. In vivo, Rigosertib sodium did not exhibit hematotoxicity, liver damage, or neurotoxicity, and was a potent inhibitor of tumor growth in a variety of xenograft nude mouse models.

KEYWORDS: Rigosertib sodium | supplier | PLK1 inhibitor | ON01910 sodium | Estybon | ON-01910 sodium | ON 01910 sodium | CAS [592542-60-4] | [592542-59-1] | Non Selective (CHK2; p53) | PLK | Inhibitor | Enzymes | Novonex | ON 01910.Na

Order
Size Unit Price Stock
5 mg €95.00 In Stock
25 mg €325.00 In Stock
Special Offers
Size Unit Price Stock
2 x 5 mg €140.00 In Stock
2 x 25 mg €250.00 In Stock
Need more? Bulk Inquiry

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...